Jun. 1, 2010
Chongqing Kangwei Biotech has developed a vaccine that prevents infection by Helicobacter pylori. Helicobacter pylori is a bacterium that lives in the stomach and causes duodenal and gastric ulcers which was also linked to stomach cancer.
The vaccine against helicobacter pylori (Hp) has obtained a drug certificate last year (SFDA) and is the world's first vaccine against Hp. The drug is expected to begin commercialization by 2011.
Clinical studies with some 6,000 participants showed that the vaccine can make the mucous membrane in the stomach immune to helicobacter pylori and stop 72 percent of infections.
In China, about 200,000 people die from stomach cancer every year. Today, patients resort to antibiotics to combat Hp. Antibiotics are not only costly and cause serious side-effects, but also do not prevent the infection from reoccurring. It is expected that the vaccine will cost between 200 to 300 RMB, only 20-30% of the current treatment cost.